BLACKROCK CAPITAL ALLOC TR (BCAT) Stock Overview
USA - NYSE:BCAT - US09260U1097
14.54 USD
+0.11 (+0.76%)
14.55 USD
+0.01 (+0.07%)
BCAT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. The financial health of BCAT is average, but there are quite some concerns on its profitability. BCAT has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BCAT was profitable.
In the past year BCAT had a positive cash flow from operations.
BCAT had positive earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: BCAT reported negative operating cash flow in multiple years.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.47% | ||
| ROE | 9.62% | ||
| ROIC | 2.18% |
ROA(3y)1.93%
ROA(5y)3.01%
ROE(3y)1.54%
ROE(5y)3.06%
ROIC(3y)2.43%
ROIC(5y)1.81%
1.3 Margins
In the last couple of years the Profit Margin of BCAT has grown nicely.
In the last couple of years the Operating Margin of BCAT has grown nicely.
In the last couple of years the Gross Margin of BCAT has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 66.67% | ||
| PM (TTM) | 228.99% | ||
| GM | 69.57% |
OM growth 3Y2.53%
OM growth 5YN/A
PM growth 3Y26.3%
PM growth 5YN/A
GM growth 3Y3.11%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for BCAT has been reduced compared to 1 year ago.
There is no outstanding debt for BCAT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
BCAT has an Altman-Z score of 4.03. This indicates that BCAT is financially healthy and has little risk of bankruptcy at the moment.
BCAT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.03 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.18 indicates that BCAT may have some problems paying its short term obligations.
BCAT has a Quick Ratio of 0.18. This is a bad value and indicates that BCAT is not financially healthy enough and could expect problems in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.18 | ||
| Quick Ratio | 0.18 |
3. Growth
3.1 Past
The earnings per share for BCAT have decreased strongly by -22.05% in the last year.
Measured over the past years, BCAT shows a quite strong growth in Earnings Per Share. The EPS has been growing by 19.50% on average per year.
The Revenue for BCAT has decreased by -15.37% in the past year. This is quite bad
The Revenue has been decreasing by -7.40% on average over the past years.
EPS 1Y (TTM)-22.05%
EPS 3Y19.5%
EPS 5YN/A
EPS Q2Q%-25.2%
Revenue 1Y (TTM)-15.37%
Revenue growth 3Y-7.4%
Revenue growth 5YN/A
Sales Q2Q%-21.43%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
BCAT is valuated reasonably with a Price/Earnings ratio of 9.57.
The average S&P500 Price/Earnings ratio is at 26.89. BCAT is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.57 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.71 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
BCAT has a Yearly Dividend Yield of 21.21%, which is a nice return.
Compared to an average S&P500 Dividend Yield of 2.31, BCAT pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 21.21% |
5.2 History
BCAT has been paying a dividend for over 5 years, so it has already some track record.
BCAT has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years2
Div Non Decr Years4
5.3 Sustainability
228.48% of the earnings are spent on dividend by BCAT. This is not a sustainable payout ratio.
DP228.48%
EPS Next 2YN/A
EPS Next 3YN/A
14.54
+0.11 (+0.76%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)
Earnings (Next)
Inst Owners21.73%
Inst Owner Change0.33%
Ins Owners0.04%
Ins Owner Change0%
Market Cap1.52B
Revenue(TTM)69.00M
Net Income(TTM)158.00M
Analysts0
Price TargetN/A
Short Float %0.53%
Short Ratio1.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 21.21% |
Yearly Dividend2.65
Dividend Growth(5Y)N/A
DP228.48%
Div Incr Years2
Div Non Decr Years4
Ex-Date
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.57 | ||
| Fwd PE | N/A | ||
| P/S | 22.08 | ||
| P/FCF | 3.71 | ||
| P/OCF | 3.71 | ||
| P/B | 0.93 | ||
| P/tB | 0.93 | ||
| EV/EBITDA | N/A |
EPS(TTM)1.52
EY10.45%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)3.92
FCFY26.98%
OCF(TTM)3.92
OCFY26.98%
SpS0.66
BVpS15.67
TBVpS15.67
PEG (NY)N/A
PEG (5Y)N/A
Graham Number23.15
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.47% | ||
| ROE | 9.62% | ||
| ROCE | 2.76% | ||
| ROIC | 2.18% | ||
| ROICexc | 2.18% | ||
| ROICexgc | 2.18% | ||
| OM | 66.67% | ||
| PM (TTM) | 228.99% | ||
| GM | 69.57% | ||
| FCFM | 595.65% |
ROA(3y)1.93%
ROA(5y)3.01%
ROE(3y)1.54%
ROE(5y)3.06%
ROIC(3y)2.43%
ROIC(5y)1.81%
ROICexc(3y)2.43%
ROICexc(5y)1.81%
ROICexgc(3y)2.46%
ROICexgc(5y)1.84%
ROCE(3y)3.07%
ROCE(5y)2.33%
ROICexgc growth 3Y13.87%
ROICexgc growth 5YN/A
ROICexc growth 3Y14.48%
ROICexc growth 5YN/A
OM growth 3Y2.53%
OM growth 5YN/A
PM growth 3Y26.3%
PM growth 5YN/A
GM growth 3Y3.11%
GM growth 5YN/A
F-Score5
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 260.13% | ||
| Current Ratio | 0.18 | ||
| Quick Ratio | 0.18 | ||
| Altman-Z | 4.03 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.05%
EPS 3Y19.5%
EPS 5YN/A
EPS Q2Q%-25.2%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.37%
Revenue growth 3Y-7.4%
Revenue growth 5YN/A
Sales Q2Q%-21.43%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.86%
EBIT growth 3Y-5.06%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y41.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.48%
OCF growth 3YN/A
OCF growth 5YN/A
BLACKROCK CAPITAL ALLOC TR / BCAT FAQ
What does BLACKROCK CAPITAL ALLOC TR do?
BlackRock Capital Allocation Term Trust is a US-based company operating in industry. The company is headquartered in Wilmington, Delaware. The company went IPO on 2020-09-25. BlackRock Capital Allocation Term Trust (the Trust) is a diversified, closed-end management investment company. The Trust’s investment objectives are to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust invests in a portfolio of equity and debt securities. Generally, the Trust’s portfolio will include both equity and debt securities. At any given time, however, the Trust may emphasize either debt securities or equity securities. The Trust utilizes an option writing (selling) strategy in an effort to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns. The Trust can invest in all types of debt securities, including the United States and foreign government bonds, corporate bonds, convertible bonds, municipal bonds, structured notes, credit-linked notes, loan assignments and participations, and others. The Trust’s investment adviser is BlackRock Advisors, LLC.
What is the current price of BCAT stock?
The current stock price of BCAT is 14.54 USD. The price increased by 0.76% in the last trading session.
How is the ChartMill rating for BLACKROCK CAPITAL ALLOC TR?
BCAT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.